Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients

Comparison of Sedative Effects of Sevoflurane, Propofol and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Mechanically Ventilated Patients

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02394418

Enrollment

Registered

2015-03-20

Start date

2017-09-01

Completion date

2018-08-31

Last updated

2019-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Brief summary

Assessment of sedative effects of sevoflurane, dexmedetomidine and propofol on the clinical course of delirium, SIRS and neuroinflammation in mechanically ventilated patients using CAM-ICU scale, GSK-3beta and protein S100b in serum.

Interventions

DRUGSevoflurane

Treatment of delirium by inhaled sevoflurane

DRUGPropofol

Treatment of delirium by propofol i.v. infusion

DRUGDexmedetomidine

Treatment of delirium by dexmedetomidine i.v. infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* presence of delirium

Exclusion criteria

* presence of Alzheimer's disease * any mental disorder * presence of cancer

Design outcomes

Primary

Measure	Time frame	Description
Duration of Delirium	up to 5 days	Delirium assessment by CAM-ICU scale

Secondary

Measure	Time frame
Change of protein S100b in serum	from delirium onset up to 5 days
Change of GSK-3beta in serum	from delirium onset up to 5 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026